TNFRSF1B +676 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoradiotherapy

Xiaoxiang Guan1, Zhongxin Liao2*, Hongxia Ma1, Ji Qian1, Zhensheng Liu1, Xianglin Yuan3, Daniel Gomez2, Ritsuko Komaki2, Li-E Wang1 and Qingyi Wei1*

Abstract

Background: The dysregulation of gene expression in the TNF-TNFR superfamily has been involved in various human cancers including non-small cell lung cancer (NSCLC). Furthermore, functional polymorphisms in TNF-α and TNFRSF1B genes that alter gene expression are likely to be associated with risk and clinical outcomes of cancers. However, few reported studies have investigated the association between potentially functional SNPs in both TNF-α and TNFRSF1B and prognosis of NSCLC patients treated with chemoradiotherapy.

Methods: We genotyped five potentially functional polymorphisms of TNF-α and TNFRSF1B genes [TNF-α -308 G>A (rs1800629) and -1031 T>C (rs1799964); TNFRSF1B +676 T>G (rs1061622), -1709A>T(rs652625) and +1663A>G (rs1061624)] in 225 NSCLC patients treated with chemoradiotherapy or radiotherapy alone. Kaplan-Meier survival analysis, log-rank tests and Cox proportional hazard models were used to evaluate associations between these variants and NSCLC overall survival (OS).

Results: We found that the TNFRSF1B +676 GG genotype was associated with a significantly better OS of NSCLC (GG vs. TT: adjusted HR = 0.38, 95% CI = 0.15-0.94; GG vs. GT/TT: adjusted HR = 0.35, 95% CI = 0.14-0.88). Further stepwise multivariate Cox regression analysis showed that the TNFRSF1B +676 GG was an independent prognosis predictor in this NSCLC cohort (GG vs. GT/TT: HR = 0.35, 95% CI = 0.14-0.85), in the presence of node status (N2-3 vs. N0-1: HR = 1.60, 95% CI = 1.09-2.35) and tumor stage (T3-4 vs. T0-2: HR = 1.48, 95% CI = 1.08-2.03).

Conclusions: Although the exact biological function for this SNP remains to be explored, our findings suggest a possible role of TNFRSF1B +676 T>G (rs1061622) in the prognosis of NSCLC. Further large and functional studies are needed to confirm our findings.

Keywords: TNF-α, TNFRSF1B, polymorphism, non-small cell lung cancer, survival
administer the optimal therapy in the management of NSCLC patients.

Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory cytokine produced by activated macrophages and exerts its action through binding to its two cognate cell surface receptors, TNFRSF1A/TNFRI (p55/60) and TNFRSF1B/TNFRII (p75/80). It is well known that TNF and its superfamily members have both beneficial and harmful activities, playing a role as a “double-edged sword” [5]. Although TNF was discovered as a cytokine that could kill tumor cells, it is now clear that TNF can also contribute to tumorigenesis by mediating the proliferation, invasion and metastasis of tumor cells [5]. The dysregulation of gene expression in the TNF/TNFR superfamily has been reported to be involved in the development and prognosis of various human cancers including NSCLC [6-12]. For example, studies indicated that high serum concentrations of TNF were associated with a significantly longer survival in NSCLC patients after chemotherapy [12] and that TNFRSF1B had a significantly different expression profile in 5-FU-non-responding and responding liver cancer patients [11]. Additionally, recent reports found that TNF-α was involved in the pathogenesis of radiation-induced lung injury [13] and that inhibiting the TNF-α pathway was a novel radioprotection strategy [14]. These observations suggest that TNF and TNFRSF1B may play a role in patients’ treatment response, toxicity, and survival. Thus, genetic variations in TNF and TNFRSF1B that alter gene expression and/or protein production may be potential candidates for prognosis predictors of NSCLC patients.

TNF-α and TNFRSF1B genes are highly polymorphic, and several functional single nucleotide polymorphisms (SNPs) in these two genes have been identified, which may contribute to differences in expression levels of the genes or protein products [15-20]. Of a particular significance are two TNF-α SNPs (SNP -308 G>A and -1031 T>C in the promoter region) and one TNFRSF1B SNP (+676 T>G in exon 6), which have been widely investigated for their associations with susceptibility to and progression and prognosis of various cancers [21-37]. However, to the best of our knowledge, no published study has investigated associations between potentially functional SNPs of these two genes and prognosis of NSCLC patients treated with chemoradiotherapy. Therefore, we performed a case-only study with 225 NSCLC patients treated with chemoradiotherapy or radiotherapy alone to investigate whether these three SNPs (SNP -308 G>A and -1031 T>C in TNF-α, and +676 T>G) as well as the other two potentially functional SNPs (-1709A>T and +1663A>G in TNFRSF1B) are associated with overall survival of NSCLC.

Methods

Study population

Epidemiological and clinical data were available from a larger dataset of 576 NSCLC patients who were treated with definitive radiation at The University of Texas M. D. Anderson Cancer Center (Houston, TX) between 1998 and 2006. The detailed information about these subjects has been described elsewhere [38]. After the exclusion of those patients who had surgical resection or had been treated elsewhere before coming to M. D. Anderson, a total of 225 NSCLC patients treated with chemoradiotherapy or radiotherapy alone were included in this analysis; The study was approved by the M. D. Anderson Cancer Center institutional review board in compliance with Health Insurance Portability and Accountability Act (HIPAA) regulations.

SNP selection

We screened the NCBI dbSNP database (http://www.ncbi.nlm.nih.gov/, build 131) and Hapmap database (http://www.hapmap.org/, Rel 27) for common, potentially functional SNPs with a minor allele frequency (MAF) ≥ 0.05 in CEU populations, i.e., those SNPs located in the 5’ near gene, 5’- and 3’-untranslated regions and coding region of TNF-α and TNFRSF1B. Meanwhile, linkage disequilibrium (LD) analysis and bioinformatics prediction by SNPinfo (http://snpinfo.niehs.nih.gov/) [39] were also performed to optimize SNP selection. Finally, a total of five SNPs (TNF-α -308 G>A, TNF-α -1031 T>C, and TNFRSF1B +676 T>G, TNFRSF1B -1709A>T and TNFRSF1B+1663A>G) were selected for genotyping. Among these, three SNPs are located in the promoter regions of the genes (TNF-α -308 G>A, TNF-α -1031 T>C, and TNFRSF1B -1709A>T), which are predicted to affect the binding of some transcription factors. One SNP (TNFRSF1B +676 T>G) causes a missense change and the other (TNFRSF1B +1663A>G) is located in the 3’-untranslated region, which may affect miRNA binding.

Genotyping

Genomic DNA was isolated from the buffy coat fraction of each blood sample with a Blood Mini Kit (Qiagen, Valencia, CA) according to the manufacturer’s instructions. Genotypes of the three selected SNPs (SNP -308 G>A and -1031 C>T in TNF-α, and -1709A>T in TNFRSF1B ) were determined by the primer-introduced restriction analysis (PIRA)-PCR assay. The primers used for TNF-α -308 G>A, TNF-α -1031 T>C and TNFRSF1B -1709A>T were 5’-GCAATAGTTGTGAGGCCATG-3’ (sense) and 5’-TTGGAGATTGGAAGCACAACACAC-3’ (anti-sense); 5’-GGGAACAAAAGGAGAAGCTGAAACA-3’ (sense) and 5’-GGGGGGTCCCCCATACTC-3’ (antisense).
GACTT-3’ (anti-sense); and 5’-CCACACACCTCAAGACCCAATGAG-3’ (sense) and 5’-CTTGGATTCTGTCCCAAGATGG-3’ (anti-sense), respectively. The mismatches G, C and A were respectively introduced into the sense primers at 6 bp, 2 bp and 2 bp from these three polymorphic sites to create NcoI, NlaIII and MlyI restriction sites. Additionally, TNFRSF1B +676T>G and +1663A>G were genotyped by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method with the primers 5’-CTCCTCCTCCACGCCTGTAACG-3’ (sense) and 5’-CCACACTGGAAGAGCGAAGTC-3’ (anti-sense), and 5’-AGGCCCCCACCACTAGGACTCT-3’ (sense) and 5’-GTTGTTGGAAAGCCTCTGCTG-3’ (anti-sense), respectively. The following PCR conditions were performed: 5 min of initial denaturation at 95°C followed by 35 cycles of 30 s at 95°C, 45 s at 64°C (TNF-α -308 G>A) or 59°C (TNF-α -1031 C>T) or 64°C (TNFRSF1B +676 T>G) or 59°C (TNFRSF1B -1709A>T) or 62°C (TNFRSF1B +1663A>G), respectively; 45 s at 72°C; and a final 10-min step at 72°C for final extension. All the PCR products were digested with the restriction enzymes overnight (NcoI for TNF-α -308 G>A, NlaIII for TNF-α -1031 C>T and TNFRSF1B +676 T>G, and MlyI for TNFRSF1B -1709A>T) and MspAI for TNFRSF1B (+1663A>G), and the products were separated in 3% MetaPhor agarose gel. After completion of gel electrophoresis, the TNF-α -308 GG genotype produced two bands (127- and 18-bp), AA produced a single band (145-bp), and AG displayed all three bands (145-, 127-, and 18-bp) (Figure 1A); the TNF-α -1031 CC genotype resulted in two bands of 108- and 86-bp, TT produced three bands of 108-, 62- and 24-bp, and CT produced four bands (108-, 86-, 62- and 24-bp) (Figure 1B); the TNFRSF1B +676 TT genotype produced two bands (200- and 48-bp), GG produced a single band (248-bp), and TG displayed all three bands (248-, 200- and 48-bp) (Figure 1C); TNFRSF1B -1709 TT genotype produced two bands of 136- and 24-bp, AA resulted in a single 160-bp band, and TA displayed all three bands (160-, 136- and 24-bp) (Figure 1D); and TNFRSF1B +1663AA resulted in a single 128-bp band, GG genotype produced another single band of 104-bp, and GA displayed all two bands (128-, and 104-bp) (Figure 1E). Genotyping was performed without knowing the subjects’ disease status. Two research assistants independently read the gel pictures and performed the repeated assays, if they did not reach a consensus on the tested genotype. About 10% of the samples were randomly selected to perform the repeated assays, and the results were 100% concordant.

Statistical analysis
The two-sided χ² tests were performed to determine any statistically significant differences in the distributions of the TNF-α and TNFRSF1B genotypes by demographic variables and clinical features. Median survival time (MST) was calculated, and mean survival time was presented when the MST could not be calculated. Kaplan-Meier estimates were used to estimate overall survival (OS) among four genotype groups, and the log-rank test was used to test for equality of the survival distributions. Univariate analysis and multivariate Cox proportional hazards models were conducted to estimate the effect of each genotype on survival with or without the presence of known prognostic factors. Cox stepwise hazards regression model was also conducted to determine independently predictors of NSCLC prognosis, with a significance level of 0.050 for entering and 0.051 for removing the respective explanatory variables. Haplotype frequencies and individual haplotypes based on the observed genotypes were generated by using SAS PROC HAPLOTYPE. Analyses were performed by using SAS statistical package version 9.1 (SAS Institute Inc., Cary, NC).

Results
Patient characteristics and clinical features
As shown in Table 1, 225 patients were included in the final analyses, of which 155 deaths were observed during the follow-up period, and the overall MST was 23 months. Among the cases, 79 (35.1%) were adenocarcinoma, 71 (31.6) squamous cell carcinoma, and 75 (33.3%) other type of NSCLC. According to the AJCC 6th edition stage grouping criteria [40], 33 cases (14.7%) were stage I-II, and 192 (85.3%) were stage III-IV. In this study, all cases received radiotherapy with a median radiation dose of 63.0 (range 50.4-84.0) Gy at 1.8 to 2 Gy per fraction once a day. Platinum and taxane-based chemotherapy was also given to 163 (72.4%) patients. None of the patients received surgery. Log-rank test showed that, in this study population, there were no significant differences in NSCLC-specific survival by age (log-rank P = 0.117), ethnicity (P = 0.827), smoking status (P = 0.457), histology (P = 0.092), Karnofsky’s performance scores (KPS, P = 0.405), chemotherapy status (P = 0.407) and radiotherapy dose (P = 0.706). However, sex, tumor stage, and node status were significantly associated with MST of NSCLC (log-rank P = 0.036, 0.010 and 0.023, respectively). Because these variables may be confounding factors for the effect of the genotypes on OS, they were further adjusted in the multivariable analysis.

TNF-α and TNFRSF1B genotypes and NSCLC survival
The genotype distributions of the five SNPs in TNF-α and TNFRSF1B and their associations with OS are summarized in Table 2. In all patients, only genotypes of TNFRSF1B +676 G>T (rs1061622) were statistically significantly associated with OS (log-rank P = 0.040 in an
additive model, Figure 2A; log-rank $P = 0.014$ in a recessive model, Figure 2B). After adjustment for age, sex, ethnicity, smoking status, tumor histology, Karnofsky’s performance scores, tumor stage, application of chemotherapy and radiotherapy dose, the TNFRSF1B +676 GG variant homozygous genotype remained to be associated with a significantly decreased risk of death from NSCLC (adjusted HR = 0.38, 95% CI = 0.15-0.94 for GG vs. TT; adjusted HR = 0.35, 95% CI = 0.14-0.88 for GG vs. GT/TT), but this association was not observed for the other four SNPs investigated in this study.

In order to confirm an independent role of SNPs in NSCLC survival, we further performed a multivariate stepwise analysis with selected demographic characteristics and clinical features in different genetic models of TNFRSF1B +676 T>G (rs1061622) on NSCLC survival. Three variables (tumor stage, node status and rs1061622 GG vs. GT/TT) were identified in the regression model with a significance level of 0.050 for entering and 0.051 for removing a variable (Table 3), suggesting the independent effect of these three factors on death risk of NSCLC. When age and sex were forced into the final model, the rs1061622 GG genotype remained a significantly favorable predictor for NSCLC survival (GG vs. GT/TT: HR = 0.39, 95% CI = 0.16-0.95) (Table 3).
Stratification analysis and haplotype analysis

As shown in Figure 3A-E, we further evaluated cumulative survival in subgroups by TNFRSF1B +676 T>G (rs1061622) genotypes and selected factors including age, ethnicity, tumor stage and node status. The longest survival was observed in subgroups with both rs1061622 GG and age ≤ 62 years (MST = 44.0 months), or white ethnicity (MST = 48.3 months), or T0-2 tumors (MST = 48.3 months), or N0-1 tumors (MST = 44.0 months), compared with the poorest survival in subgroups with both rs1061622 GT/TT and age>62 years (MST = 20.7 months), or non-white (MST = 21.0 months), or T3-4 tumors (MST = 18.2 months), or N0-1 tumors (MST = 29.2 months); however, small sample size in these subgroups might have led to a suboptimal statistical power to detect a statistical difference in the survival time. We also conducted the stratification analysis by histology and different treatments, but the numbers of patients in subgroups were too small, and no significant results were found in every stratum (data not shown).

We also evaluated the combined effect of these polymorphisms on NSCLC survival by using the haplotype analysis. The results showed that TNF-α -308G/-1031T (GT) and TNFRSF1B +676T/+1663A/-1709A (TAA) were the most common haplotypes in the patients with the frequencies of 63.3% and 40.2%, respectively. However, we did not found significant associations between other haplotypes and OS of NSCLC.

| Variables                  | Patients No. (%) | Deaths No. (%) | MST (Months) | Log-rank P* |
|----------------------------|------------------|----------------|--------------|------------|
| Age ≤62 years              | 111 (49.3)       | 72 (46.5)      | 25.6         | 0.117      |
| Age >62 years              | 114 (50.7)       | 83 (53.5)      | 21.1         |            |
| Gender Female              | 102 (45.3)       | 65 (41.9)      | 26.7         | 0.036      |
| Gender Male                | 123 (54.5)       | 90 (58.1)      | 22.3         |            |
| Ethnicity White            | 162 (72.0)       | 117 (75.5)     | 23.5         | 0.027      |
| Ethnicity Non-White        | 63 (28.0)        | 38 (24.5)      | 22.3         |            |
| Smoking Status Ever        | 205 (91.5)       | 143 (92.9)     | 23.4         | 0.457      |
| Smoking Status Never       | 19 (8.5)         | 11 (7.1)       | 21.1         |            |
| Histology Adenocarcinoma   | 79 (35.1)        | 48 (31.0)      | 27.3         | 0.092      |
| Histology Squamous cell    | 71 (31.6)        | 51 (32.9)      | 23.2         |            |
| Histology Others b         | 75 (33.3)        | 56 (36.1)      | 19.0         |            |
| Karnofsky’s performance (KPS) 90-100 | 51 (25.4) | 34 (22.7) | 25.1 | 0.405 |
| Karnofsky’s performance (KPS) 80 | 118 (58.7) | 90 (60.0) | 22.1 |          |
| Karnofsky’s performance (KPS) <80 | 32 (15.9) | 26 (17.3) | 21.1 |          |
| Tumor stage T0-2           | 127 (57.2)       | 81 (52.3)      | 26.9         | 0.010      |
| Tumor stage T3-4           | 95 (42.8)        | 74 (47.7)      | 19.2         |            |
| Node status N0-1           | 59 (26.7)        | 35 (22.6)      | 29.0         | 0.023      |
| Node status N2-3           | 162 (73.3)       | 120 (77.4)     | 20.7         |            |
| Chemotherapy Yes           | 163 (72.4)       | 113 (72.9)     | 26.9         | 0.407      |
| Chemotherapy No            | 62 (27.6)        | 42 (27.1)      | 22.1         |            |
| Radiotherapy dose ≤63.0 Gy | 115 (51.1)       | 77 (49.7)      | 22.7         | 0.706      |
| Radiotherapy dose >63.0 Gy | 110 (48.9)       | 78 (50.3)      | 25.1         |            |

MST: median survival time; KPS: Karnofsky’s performance scores
* Log-rank test.
* Others include large cell, undifferentiated and mixed-cell carcinomas.
* Some missing data.
* The median radiotherapy dose is 63 Gy.

Table 1 Characteristics of patients (N = 225) and overall survival (OS)
patients, compared to the most common haplotypes (data not shown), which is likely due to limited study power.

**Discussion**

In the present study, we examined the effect of five selected polymorphisms in *TNF-α* and *TNFRSF1B* on survival of NSCLC patients treated with chemoradiotherapy or radiotherapy alone. We found that the *TNFRSF1B* +676 GG (rs1061622) variant homozygous genotype was associated with a significantly improved survival of NSCLC in this non-Hispanic patient population. Such an effect was not observed for other SPNs under investigation.

Tumor necrosis factor-alpha (*TNF-α*) executes multiple functions in immunity, inflammation, differentiation, control of cell proliferation, and apoptosis through distinct receptors known as TNF receptor type I (*TNFR1*) and type II (*TNFR2*) [5]. Expression levels of *TNF-α* and its receptors have been linked to development and treatment outcomes of solid tumors including NSCLC [6,7,10]. The expression of *TNF-α* is mostly regulated at the transcriptional level, and polymorphisms within the *TNF-α* promoter have been related to *TNF-α* levels.

**Table 2 Associations between *TNF-α* and *TNFRSF1B* genotypes and overall survival of NSCLC patients**

| Genotypes             | No. of patients | No. of Deaths | MST (months) | Crude HR (95% CI) | Adjusted HR (95% CI) \* | Adjusted P \* |
|-----------------------|-----------------|---------------|--------------|-------------------|------------------------|--------------|
| *TNF-α* -308 G>A (rs1800629) |                 |               |              |                   |                        |              |
| GG                    | 163             | 112 (68.7)    | 23.5         | 1.00              | 1.00                   | 1.00         |
| AG                    | 56              | 39 (69.6)     | 23.2         | 1.04 (0.72-1.50)  | 0.95 (0.65-1.40)       | 0.802        |
| AA                    | 6               | 4 (66.7)      | 18.1         | 1.18 (0.44-3.21)  | 1.10 (0.39-3.11)       | 0.859        |
| AG+AA                 | 61              | 43 (70.5)     | 23.1         | 1.05 (0.74-1.50)  | 0.96 (0.67-1.40)       | 0.849        |
| AG+GG                 | 219             | 151 (68.9)    | 23.4         | 1.00              | 1.00                   | 1.00         |
| AA                    | 6               | 4 (66.7)      | 18.1         | 1.17 (0.43-3.16)  | 1.11 (0.40-3.13)       | 0.840        |
| *TNF-α* -1031T>C (rs1799964) |                 |               |              |                   |                        |              |
| TT                    | 137             | 95 (69.3)     | 23.4         | 1.00              | 1.00                   | 1.00         |
| CT                    | 77              | 50 (64.9)     | 22.1         | 0.96 (0.68-1.35)  | 0.89 (0.62-1.28)       | 0.542        |
| CC                    | 11              | 10 (90.9)     | 23.1         | 1.28 (0.67-2.46)  | 1.41 (0.70-2.87)       | 0.341        |
| CT+CC                 | 88              | 60 (68.2)     | 23.1         | 1.00 (0.72-1.38)  | 0.95 (0.68-1.34)       | 0.785        |
| CT+TT                 | 214             | 145 (67.8)    | 23.4         | 1.00              | 1.00                   | 1.00         |
| CC                    | 11              | 10 (90.9)     | 23.1         | 1.30 (0.68-2.47)  | 1.46 (0.73-2.94)       | 0.289        |
| *TNFRSF1B* +676 T>G (rs1061622) |                 |               |              |                   |                        |              |
| TT                    | 124             | 85 (68.5)     | 23.4         | 1.00              | 1.00                   | 1.00         |
| GT                    | 90              | 65 (72.2)     | 21.8         | 1.10 (0.80-1.52)  | 1.19 (0.84-1.69)       | 0.323        |
| GG                    | 11              | 5 (45.5)      | 41.1 \*     | 0.36 (0.14-0.88)  | 0.38 (0.15-0.94)       | 0.037        |
| GT+GG                 | 101             | 70 (69.5)     | 23.2         | 0.96 (0.70-1.31)  | 1.01 (0.72-1.42)       | 0.937        |
| GT+TT                 | 214             | 150 (70.1)    | 22.7         | 1.00              | 1.00                   | 1.00         |
| GG                    | 11              | 5 (45.5)      | 41.1 \*     | 0.34 (0.14-0.84)  | 0.35 (0.14-0.88)       | 0.026        |
| *TNFRSF1B* -1709A>T (rs652625) |                 |               |              |                   |                        |              |
| AA                    | 207             | 144 (69.6)    | 23.2         | 1.00              | 1.00                   | 1.00         |
| AT                    | 15              | 9 (60.0)      | 27.8         | 0.86 (0.44-1.69)  | 0.85 (0.42-1.71)       | 0.649        |
| TT                    | 3               | 2 (66.7)      | 15.1         | 0.94 (0.23-3.82)  | 1.02 (0.23-4.47)       | 0.976        |
| AT+TT                 | 18              | 11 (61.1)     | 26.7         | 0.88 (0.47-1.62)  | 0.87 (0.46-1.67)       | 0.685        |
| AT+AA                 | 222             | 153 (68.9)    | 23.4         | 1.00              | 1.00                   | 1.00         |
| TT                    | 3               | 2 (66.7)      | 15.1         | 0.95 (0.24-3.85)  | 1.05 (0.24-4.58)       | 0.946        |
| *TNFRSF1B* +1663A>G (rs1061624) |                 |               |              |                   |                        |              |
| AA                    | 67              | 46 (68.7)     | 23.4         | 1.00              | 1.00                   | 1.00         |
| AG                    | 89              | 63 (70.8)     | 21.1         | 1.06 (0.73-1.53)  | 0.98 (0.68-1.43)       | 0.921        |
| GG                    | 62              | 41 (66.1)     | 28.1         | 0.84 (0.56-1.26)  | 0.79 (0.52-1.20)       | 0.269        |
| AG+GG                 | 151             | 104 (68.9)    | 24.0         | 1.03 (0.73-1.46)  | 0.96 (0.67-1.37)       | 0.824        |
| AG+AA                 | 156             | 109 (69.9)    | 22.7         | 1.00              | 1.00                   | 1.00         |
| GG                    | 62              | 41 (66.1)     | 28.1         | 0.84 (0.59-1.20)  | 0.81 (0.56-1.18)       | 0.275        |

MST: median survival time; HR: hazard ratio

\*Adjusted for age, gender, ethnicity, smoking status, tumor histology, KPS, tumor stage, node status, application of chemotherapy and radiotherapy dose.

\*Mean survival time was provided when MST could not be calculated.

Guan et al. BMC Cancer 2011, 11:447
http://www.biomedcentral.com/1471-2407/11/447

Page 6 of 10
[15,23]. For example, TNF-α-308 G/A in the promoter of TNF-α has been reported to be associated with higher expression levels of TNF-α [41] and thus susceptibility to numerous cancers, including cancers of the stomach [25], breasts [34], oral cavity [31,32], bladder [35] and lung [25]. Additionally, several studies also found that TNF-α-308 G/A and another SNP in the promoter of TNF-α (-1031C>T, rs1799964) were significantly associated with prognosis of bladder cancer and breast cancer [28,29,36], clinical characteristics of colorectal cancer, and severity of lung cancer [25]. However, no significant associations between these two SNPs and NSCLC survival were found in our study, which was consistent with recent data that suggested the lack of associations between TNF-α-308 G/A or TNF-α-1031 T>C and the prognosis of several other cancers, including gastric cancer [42], colorectal cancer [43], Hodgkin’s lymphoma [44], and breast cancer [45]. Such a discrepancy of reported studies might be explained by different tumor sites and tumor progression features, ethnic difference with diverse genetic background, different therapeutic strategies, and either false negative or false positive results because of the small sample sizes in previously published studies.

Interestingly, logistic and stepwise regression analysis in our study indicated that TNFRSF1B rs1061622 GG might be an independent predictor for survival of NSCLC patients treated with chemoradiotherapy or

Figure 2 Overall survival curves by genotypes of TNFRSF1B +676 T>G (rs1061622) in additive model (A) and recessive model (B). The \( P \) values were obtained from the unadjusted log-rank test. * Mean survival time was provided when MST could not be calculated.
radiotherapy alone. The TNFRSF1B is the principal TNF receptor found on circulating T lymphocytes, which functions both as a TNF antagonist by neutralizing it and as an agonist by facilitating interaction between TNF and TNFR1 at the cell surface [46]. rs1061622 is located in the exon 6 of *TNFRSF1B* (M196R) that causes a functional amino acid change from methionine (M) to arginine (R) [20], which is postulated to affect the proteolytic cleavage of the membrane bound TNFRSF1B to a soluble form as well as TNF binding and/or TNF induced apoptosis by impaired NF-κB signaling [47,48].

However, the results from published studies on associations between rs1061622 and prognosis of cancers were controversial rather than conclusive. For example, a Tunisian study showed significant associations of *TNFRSF1B* +676 T>G (rs1061622) with susceptibility and survival of breast cancer patients [26], but another Japanese study suggested no association between this SNP and prognosis of esophageal squamous cell carcinoma [49]. Up to now, no published study investigated the association between *TNFRSF1B* +676 T>G (rs1061622) and lung cancer survival, and the exact biological mechanism underlying this association in our study remains to be investigated. It is possible that this SNP affects the function of *TNFRSF1B* and enhances radiotherapy or chemotherapy efficacy through inhibiting tumor therapy resistance. Another possibility is that this SNP may change the expression level of *TNFRSF1B* and influence the character of immunological response to infection in lung cancer patients, finally resulting in

| Variables                                      | β     | SE   | HR   | 95% CI          | P    |
|------------------------------------------------|-------|------|------|-----------------|------|
| **Stepwise Regression Analysis**               |       |      |      |                 |      |
| Node status (N2-3 vs. N0-1)                    | 0.472 | 0.195| 1.60 | 1.09-2.35       | 0.015|
| Tumor stage (T3-4 vs. T0-2)                    | 0.392 | 0.162| 1.48 | 1.08-2.03       | 0.016|
| *TNFRSF1B* +676 T>G (GG vs GT/TT)              | -1.061| 0.457| 0.35 | 0.14-0.85       | 0.020|
| **Final Regression Model**                     |       |      |      |                 |      |
| Age (>62 years vs. ≤62 years)                  | 0.288 | 0.165| 1.33 | 0.97-1.84       | 0.081|
| Sex (Male vs Female)                           | 0.252 | 0.165| 1.29 | 0.93-1.78       | 0.126|
| Node status (N2-3 vs. N0-1)                    | 0.511 | 0.196| 1.67 | 1.14-2.45       | 0.009|
| Tumor stage (T3-4 vs. T0-2)                    | 0.392 | 0.163| 1.48 | 1.08-2.04       | 0.016|
| *TNFRSF1B* +676 T>G (GG vs GT/TT)              | -0.954| 0.459| 0.39 | 0.16-0.95       | 0.038|

SE: standard error; HR: hazard ratio

Table 3 Results of stepwise Cox regression analysis on NSCLC

Figure 3 Overall survival curves by genotypes of *TNFRSF1B* +676 T>G (rs1061622) and selected factors including age (A), ethnicity (B), tumor stage (C) and node status(D). The P values were obtained from the unadjusted log-rank test. *Mean survival time was provided when MST could not be calculated.*
the difference of survival in NSCLC [50]. Furthermore, we also found that cumulative survival was different in subgroups by TNFRSF1B +676 T>G (rs1061622) genotypes and selected factors including age, ethnicity, tumor stage and node status. Although our sample size was relatively small in these subgroups, it provided a clue that effect of this SNP on prognosis of NSCLC may be dependent on patients’ characteristics and clinical features as well. However, the exact functional relevance of this SNP in the prognosis of NSCLC patients treated with chemoradiotherapy remains to be explored.

Although our study reported some new findings about polymorphisms of TNF and TNFRSF1B genes in NSCLC patients, several potential limitations should be taken into consideration. Firstly, our sample size is relatively small with a limited statistical power to evaluate interactions between the studied polymorphisms and clinical factors including tumor stage and node status. For the same reason, the results from our subgroups by TNFRSF1B +676 T>G (rs1061622) genotypes and selected factors need validation by larger studies. Secondly, only five potentially functional SNPs in TNF and TNFRSF1B were included in our study, which is far from comprehensive. Indeed, both genes are highly polymorphic, and it is possible that some important SNPs may have been missed or the observed association may have been due to other polymorphisms in LD with the studied ones. Again, much larger studies would have the statistical power to confirm the associations of more SNPs with OS in such a patient population.

Conclusion
In summary, in this cohort of NSCLC patients, we identified a possible role of TNFRSF1B +676 T>G in the prognosis of NSCLC. However, replication studies with diverse ethnic groups, larger sample sizes and functional characterizations are warranted. Currently, we have ongoing projects that help continue recruiting similar patients for additional analysis in the future.

Abbreviations
TNF-α: Tumor necrosis factor-alpha; TNFR2: tumor necrosis factor receptor super family 2; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; HR: hazard ratio; CI: confidence interval; SNP: single nucleotide polymorphism; NSCLC: non-small cell lung cancer; OS: overall survival.

Acknowledgements and Funding
This study was in part supported by National Institutes of Health grants R01 ES11740 and CA131274 (to Q. W.) and CA16672 (to M. D. Anderson Cancer Center). We thank Margaret Lung for assistance in data management of the subjects and Hui Zhao for the data analysis assistance.

Author details
1Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA.
2Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, Texas 77030, USA.
3Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 13 Hangkong Lu, Wuhan 430030, China.

Authors’ contributions
XXG, QYW and ZXL designed the study and prepared the manuscript. XXG performed the experiments with the assistance from ZSL and JQ. XXG and HXM conducted the analysis with assistance from LEW. XLY, DG and RK helped to collect and organize the clinical data. HXM, QYW and LEW helped to finalize the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 11 April 2011 Accepted: 14 October 2011
Published: 14 October 2011

References
1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-917.
2. Gandara D, Narayan S, Lara PN Jr, Goldberg Z, Davies A, Lau DH, Mack P, Gumerlock P, Vijayakumar S: Integration of novel therapeutics into combined modality therapy of locally advanced non-small cell lung cancer. Clin Cancer Res 2005, 11:5057s-5062s.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
4. Nakanishi T, Tsuchiya R, Kondo H, Asamura H: Prognosis and survival after resection for bronchogenic carcinoma based on the 1997 TNM-staging classification: the Japanese experience. Ann Thorac Surg 2001, 71:1759-1764.
5. Aggarwal BB: Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003, 3:745-756.
6. Boldrini L, Calcinai A, Samantani E, Pistolesi F, Mussi A, Lucchi M, Angeletti CA, Basolo F, Fontanini G: Tumour necrosis factor-alpha and transforming growth factor-beta are significantly associated with better prognosis in non-small cell lung carcinoma: putative relation with BCL-2-mediated neovascularization. Br J Cancer 2000, 83:480-486.
7. Boldrini L, Gisfredi S, Ursino S, Lucchi M, Melli F, Mussi A, Basolo F, Fontanini G: Tumour necrosis factor-alpha: prognostic role and relationship with interleukin-8 and endothelin-1 in non-small cell lung cancer. Int J Mol Med 2006, 17:887-892.
8. Miles DW, Happerfield LC, Naylor MS, Bobrow LG, Rubens RD, Balkwill FR: Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 1994, 56:777-782.
9. Naylor MS, Stamp GW, Foulkes WD, Eccles D, Balkwill FR: Tumour necrosis factor and its receptors in human ovarian cancer. Potential role in disease progression. J Clin Invest 1993, 91:2194-2206.
10. Tran TA, Kallakury BV, Ambros RA, Ross JS: Prognostic significance of tumour necrosis factors and their receptors in nonsmall cell lung carcinoma. Cancer 1998, 83:276-282.
11. Matsuyma R, Togo S, Shimizu D, Moriyama N, Ishikawa T, Ichikawa Y, Enjo I, Kuniyuki C, Suzuki H, Hayasizaki Y, et al: Predicting 5-fluorouracil chemosensitivity of liver metastases from colorectal cancer using primary tumor specimens: three-gene expression model predicts clinical response. Int J Cancer 2006, 119:406-413.
12. Su C, Zhou C, Zhou S, Xu J. Serum cytokine levels in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Med Oncol 2010.
13. Rube CE, Wilfert F, Utzhe D, Schmid KW, Knoop R, Willich N, Schuck A, Rube C: Modulation of radiation-induced tumour necrosis factor alpha (TNF-alpha) expression in the lung tissue by pentoxifylline. Radiother Oncol 2002, 64:177-187.
14. Zhang M, Qian J, Xing X, Kong FM, Zhao L, Chen M, Lawrence TS: Inhibition of the tumor necrosis factor-alpha pathway is radioprotective for the lung. Clin Cancer Res 2008, 14:1868-1876.
15. Hayes AH, Hutchinson IV: Influence of TNF alpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 2001, 62:1191-1199.
16. Negoro K, Kinouchi Y, Hiwatashi N, Takahashi S, Takagi S, Satoh J, Shimosegawa T, Toyota T. Crohn’s disease is associated with novel polymorphisms in the 5’-flanking region of the tumor necrosis factor gene. Gastroenterology 2009; 137:1062-1068.

17. Weistandorp RG, Langermans JA, Huitinga EP, Verweij CL, Sturk A. Genetic influence on cytokine production in meningococcal disease. Lancet 1997; 349:1912-1913.

18. Wilson AG, Symons JA, McDowell TL, McDewett HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997; 94:3195-3199.

19. Bellingwer C, White PS, Maris JM, Sulman EP, Jensen SJ, LePaulier D, Stallard BJ, Goeddel DV, de Sauvage FJ, Broder GW. Physical mapping and genomic structure of the human TNF-R2 gene. Genomics 1996; 35:94-100.

20. Morita C, Honuchi T, Tsukamoto H, Hatta N, Kikuchi Y, Arinobu O, Otsuka T, Sawabe T, Hatashima S, Naganawa K et al. Association of tumor necrosis factor receptor type II polymorphism with decreased susceptibility to cancers. Cancer Sci 2007; 98:1261-1265.

21. Bayley JP, Ottenhoff TH, Verweij CL. TNF-alpha gene polymorphism: clinical and genomic structure of the human TNFR2 gene. Genomics 1996; 35:94-100.

22. Gupta R, Sharma SC, Das SN. Association of TNF-alpha and TNFR1 promoter region polymorphism with decreased susceptibility to cancers. Acta Oncol 2008; 47:166-171.

23. Hajeer AH, Hutchinson IV. TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech 2000; 50:216-228.

24. Gaudet MW, Egan KM, Lissow ska J, Newcomb PA, Brionton LA, Titus- Ernstoff L, Yearger M, Charoock S, Welsh P, Peplonska et al. Genetic variation in tumor necrosis factor alpha and lymphoxygen-alpha (TNF-LTA) and breast cancer risk. Hum Genet 2007; 121:483-490.

25. Hajeer AH, Hutchinson IV. TNF-alpha gene polymorphism: clinical and biological implications. Microsc Res Tech 2000; 50:216-228.

26. Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, Andjelic-Jelic MS, Dopudja-Pantic VB, Nagorni-Obradovic Lj M, Mitic-Miklic MM, Radovic-CDF. TNF-alpha-308 polymorphism in patients with chronic obstructive pulmonary disease and lung cancer. Nioleoplasma 2009; 56:348-352.

27. Ahinwar DK, Mandhani A, Dharaiskar A, Keswani P, Mittal RD. Association of tumor necrosis factor-alpha gene (T-1031C, C-863A, and C-857T) polymorphisms with bladder cancer susceptibility and outcome after bacille Calmette-Guerin immunotherapy. BJU Int 2009; 104:697-703.

28. Stankovic MM, Nestorovic AR, Tomovic-Sanetjenovc ND, Andjelic-Jelic MS, Popovka-Pantic VB, Nagnor-Obradovic LJ M, Mitic-Miklic MM, Radovic-CDF. TNF-alpha-308 polymorphism in patients with chronic obstructive pulmonary disease and lung cancer. Nioleoplasma 2009; 56:348-352.

29. Arinobu O, Otsuka T, Sawabe T, Hatashima S, Naganawa K et al. Association of tumor necrosis factor receptor type II polymorphism with decreased susceptibility to cancers. Cancer Lett 2001, 166:41-46.

30. Yajikais C, Seretoglou Z, Ylliotas A, Nienke E, Derka S, Vassilou S, Avgoudatos D, Neukam FW, Patsouris E, Vairaktaris E. Association of polymorphisms in Tumor Necrosis Factor Alpha and Beta genes with increased risk for oral cancer. Anticancer Res 2009; 29:2379-2386.

31. Gupta R, Sharma SC, Das SN. Association of TNF-alpha and TNFR1 promoters and 3’ UTR region of TNFR2 gene polymorphisms with gastric cancer susceptibility in human gastric carcinoma. Gastroenterology 2003; 125:364-371.

32. Fang F, Yao L, Ju X, Yu L, Wu Q. TNFa-f1 -308 G/A polymorphism is associated with breast cancer risk: a meta-analysis involving 10,184 cases and 12,911 controls. Breast Cancer Res Treat 2007; 122:267-271.

33. Jezack P, Kim EJ, Kim EG, Byun SS, Kim CS, Kim WJ. Association of bladder tumors and GA genotype of -308 nucleotide in tumor necrosis factor- alpha promoter with greater tumor necrosis factor-alpha expression. Urology 2004; 64:1052-1056.

34. Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad BB, Remadi S, Chouchane L. Genetic variation in the tumor necrosis factor-alpha promoter region and in the stress protein hsp70-2: susceptibility and prognostic implications in breast carcinoma. Breast Cancer 2001; 9:1672-1678.

35. Kadny J, Suchy J, Kluzaj-Gadobskaja E, Kaperski T, Scott RJ, Kurzawski G, Lubinski J. Clinical characteristics of tumors derived from colorectal cancer patients who harbor the tumor necrosis factor alpha-1031T/T and NOD2 3020insC polymorphism. Cancer Epidemiol. 2009; 33: 161-163.

36. Yuan X, Liao Z, Liu Z, Wang LE, Tucker SL, Mao L, Wang XS, Martel M, Komaki R, Cox JD, et al. Single nucleotide polymorphism at rs1982073: T896C of the TGFBeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. J Clin Oncol 2009; 27:3370-3378.

37. Xu Z, Taylor JA. SNPlinfo: integrating GWAS and candidate gene information into functional SNP selection for genetic association studies. Nucleic Acids Res 2009; 37:W690-695.

38. Greene FL. The American Joint Committee on Cancer: updating the strategies in cancer staging. Bull Am Coll Surg 2002; 87:13-15.

39. DAS SN, Baniasadi V, Kapura V. Association of -308 TNF-alpha promoter polymorphism with type 1 diabetes in North Indians. Int J Immunogenet 2006; 33:411-416.

40. Glas J, Tonok HP, Schneider A, Brunner G, Kopp R, Albert ED, Stolte M, Folvaczky C. Allele 2 of the interleukin-1 receptor antagonist gene is associated with early gastric cancer. J Clin Oncol 2004; 22:4746-4752.

41. Sharma R, Zucknick M, London R, Kacevski M, Liddle C, Clarke SJ. Systemic inflammatory response predicts prognosis in patients with advanced-stage colorectal cancer. Clin Cancer Res 2008; 14:331-337.

42. Hohaus S, Giachelli M, Di Fegia A, Martini M, Massini G, Vannata B, D’Albo F, Guidi F, Greco M, Pierconti F, et al. Polymorphism in cytokine genes as prognostic markers in Hodgkin’s lymphoma. Ann Oncol 2007; 18:1376-1381.

43. Smith KC, Bateman AC, Fussell HM, Howell WM. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet 2004; 31:167-173.

44. Terraglia LA, Pennica D, Goeddel DV. Lidarg passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993; 268:18542-18548.

45. Stark GL, Dickinson AM, Jackson GH, Taylor PR, Proctor SJ, Middleton PG. Tumour necrosis factor receptor type II 196M/R genotype correlates with circulating soluble receptor levels in normal subjects and with graft-versus-host disease after sibling allogeneic bone marrow transplantation. Transplantation 2003; 76:1742-1749.

46. Till A, Rosenstiel P, Krippner-Heidenreich A, Mascheretti-Croucher S, Tems J, Meier J, Chu M, Kim WJ. The Met-196-> Arg variation of human tumor necrosis factor 2 (TNFR2) affects TNF-alpha-induced apoptosis by impaired NF-kappaB signaling and target gene expression. J Biol Chem 2005; 280:5994-6004.

47. Kurohara A, Yamamoto M, Fujita M, Okuno T, Tamura T, Kadomya K, Okamura N, Nakamura T, Sakaida T. TNFRSF1B A1466G genotype is predictive of clinical efficacy after treatment with a definitive S-fluoruracil/cisplatin-based chemoadjuotherapy in Japanese patients with esophageal squamous cell carcinoma. J Exp Clin Cancer Res 2010; 29:100.

48. Sainz J, Perez E, Hassan L, Moratalla A, Romero A, Collado MD, Jurado M. Variable number of tandem repeats of TNF receptor type 2 promoter as genetic biomarker of susceptibility to develop invasive pulmonary aspergillosis. Hum Immunol 2007, 68:41-50.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/11/447/prepub

doi:10.1186/1471-2407-11-447

Cite this article as: Guan et al. TNFRSF18 +667 T>G polymorphism predicts survival of non-Small cell lung cancer patients treated with chemoadjuotherapy. BMC Cancer 2011;11:447.